Wedbush Predicts Kura Oncology's Q1 Earnings (NASDAQ:KURA)

Key Points

• Wedbush has revised its Q1 2026 earnings per share estimate for Kura Oncology down to $1.32, indicating a slight decline from the previous estimate of $1.34, while maintaining an "Outperform" rating and a price target of $36.00.
• Kura Oncology recently reported a significantly lower EPS of ($0.75), missing the consensus estimate by ($0.90), and revenue of $15.29 million, falling short of analyst expectations of $64.95 million.
• Following a series of downgrades, including a cut from Barclays from $32.00 to $11.00, Kura Oncology's stock is facing mixed ratings with a current consensus of "Moderate Buy" and a target price of $24.50.

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Wedbush dropped their Q1 2026 EPS estimates for Kura Oncology in a note issued to investors on Friday, August 8th. Wedbush analyst R. Driscoll now expects that the company will post earnings of $1.32 per share for the quarter, down from their prior forecast of $1.34. Wedbush has a "Outperform" rating and a $36.00 price objective on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million.

KURA has been the subject of several other research reports. Wall Street Zen lowered shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Mizuho lowered their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. JMP Securities lowered their target price on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research note on Monday. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Finally, Barclays lowered their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.10.

Kura Oncology Stock Up 13.6%

Shares of NASDAQ:KURA traded up $0.90 during midday trading on Monday, reaching $7.50. The company had a trading volume of 1,385,596 shares, compared to its average volume of 1,410,416. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The stock's fifty day moving average price is $6.19 and its 200-day moving average price is $6.65. The stock has a market capitalization of $650.57 million, a P/E ratio of -3.32 and a beta of 0.41. Kura Oncology has a one year low of $5.41 and a one year high of $21.57.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently added to or reduced their stakes in KURA. State of Wyoming bought a new stake in Kura Oncology during the first quarter worth approximately $48,000. Virtus ETF Advisers LLC boosted its position in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares during the period. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the first quarter valued at approximately $66,000. Flower City Capital bought a new stake in shares of Kura Oncology in the first quarter valued at approximately $79,000. Finally, Magnetar Financial LLC bought a new stake in shares of Kura Oncology in the first quarter valued at approximately $79,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.